Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Waters Corporation (WAT)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$467.60+1.67%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
16.49 → 16.52 EPS · FY ending Dec 31, 2027 · 13 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 14 to 13; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for WAT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Full-year 2026 adjusted EPS near $14.5 per share | Adjusted EPS guidance is strong at about $14.5 per share. | Intact | Adjusted EPS falls below $13.5 per share | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
WAT is a quality growth business with robust earnings quality, strong recent performance, and support from a favorable sector backdrop. Its multi-year view is intact, though confidence has eased from high to medium and management execution remains neutral overall.
The evidence tags the valuation as justified, with low signs of fragility, but also classifies WAT as expensive. It appears cheap versus peers on one comparison, while the expectations gap is slightly negative, so the market’s assumptions leave limited room for disappointment.
Near term, results and guidance have been strengthening: management raised 2026 revenue and adjusted EPS guidance, and acquired business revenue increased from the first to the second quarter. Integration is on track, but a guidance cut would be a meaningful negative; recent peer misses and a past deep miss are risks despite a low estimated miss probability.
The multi-year thesis hinges on continued delivery against higher guidance and successful integration of the acquired businesses. Near term, weakening jobs data could increase recession concerns, while continued earnings strength and higher guidance from sector peers would support the sector backdrop.
Over the next 1 to 3 years, the business setup is supported by strong results, rising guidance, and integration progress, but an expensive valuation and execution risks keep the evidence mixed. The thesis remains intact, with medium confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The acquisition of Becton, Dickinson assets adds $520 million revenue in Q1, boosting growth. |
| Intact |
| BD asset revenue falls below $480 million in any quarter |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 8 supplied quarters. Management reported: “Dr. Batra continued, “Thanks to the hard work of our teams, we are delivering ahead of schedule on our synergy and integration commitments for our acquired businesses.” ““Our Biosciences and Advanced Diagnostics Divisions are off to a strong start with a significant improvement in growth rates versus pre-close trends, due to increased execution discipline, a sharper focus on upcoming new product launches, and superb collaboration with our Analytical Sciences Division which has already enabled the realization of revenue synergies.” Delivery assessment Nov 4, 2026 |
Full-year 2026 revenue of about $6.42 billion | The company raised full-year 2026 revenue guidance to about $6.42 billion. | Intact | Full-year revenue falls below $6.0 billion | Revenue: $1.645B FY2026-Q2; GAAP. Published target: >= $6.42 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 20261,645,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$16.45 → $16.52 · observed estimates
$7.10B → $7.15B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $16.45 | $7,104,470,999 | 14 / 17 |
| 2026-07-25 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-07-26 | $16.45 | $7,104,470,999 | 14 / 17 |
| 2026-07-27 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-07-28 | $16.45 | $7,104,470,999 | 14 / 17 |
| 2026-07-29 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-07-30 | $16.45 | $7,104,470,999 | 14 / 17 |
| 2026-07-31 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-08-01 | $16.45 | $7,104,470,999 | 14 / 17 |
| 2026-08-02 | $16.46 | $7,104,470,999 | 14 / 17 |
| 2026-08-03 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-08-04 | $16.49 | $7,110,645,470 | 24 / 23 |
| 2026-08-05 | $16.46 | $7,104,470,999 | 14 / 17 |
| 2026-08-06 | $16.46 | $7,104,470,999 | 14 / 17 |
| 2026-08-08 | $16.57 | $7,131,786,290 | 24 / 23 |
| 2026-08-09 | $16.52 | $7,123,879,553 | 14 / 17 |
| 2026-08-10 | $16.52 | $7,123,879,553 | 14 / 17 |
| 2026-08-12 | $16.56 | $7,116,732,110 | 23 / 23 |
| 2026-08-13 | $16.52 | $7,123,879,553 | 14 / 17 |
| 2026-08-14 | $16.52 | $7,123,879,553 | 14 / 17 |
| 2026-08-15 | $16.52 | $7,123,879,553 | 14 / 17 |
| 2026-08-16 | $16.52 | $7,123,879,553 | 13 / 17 |
| 2026-08-17 | $16.52 | $7,123,879,553 | 13 / 17 |
| 2026-08-18 | $16.52 | $7,123,879,553 | 13 / 17 |
| 2026-08-19 | $16.52 | $7,123,879,553 | 13 / 17 |
| 2026-08-20 | $16.35 | $7,109,169,979 | 13 / 17 |
| 2026-08-21 | $16.52 | $7,126,631,956 | 14 / 17 |
| 2026-08-22 | $16.52 | $7,126,631,956 | 14 / 17 |
| 2026-08-23 | $16.52 | $7,126,631,956 | 14 / 17 |
| 2026-08-24 | $16.52 | $7,126,631,956 | 14 / 17 |
| 2026-08-25 | $16.50 | $7,126,904,683 | 14 / 17 |
| 2026-08-26 | $16.50 | $7,126,904,683 | 14 / 17 |
| 2026-08-27 | $16.50 | $7,126,904,683 | 14 / 17 |
| 2026-08-28 | $16.50 | $7,126,904,683 | 14 / 17 |
| 2026-08-29 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-08-30 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-08-31 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-01 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-02 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-03 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-04 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-05 | $16.50 | $7,126,896,042 | 14 / 17 |
| 2026-09-06 | $16.50 | $7,126,896,042 | 13 / 17 |
| 2026-09-07 | $16.50 | $7,126,896,042 | 13 / 17 |
| 2026-09-08 | $16.50 | $7,126,896,042 | 13 / 17 |
| 2026-09-09 | $16.50 | $7,126,896,042 | 13 / 17 |
| 2026-09-10 | $16.50 | $7,127,880,872 | 13 / 17 |
| 2026-09-11 | $16.50 | $7,127,880,872 | 13 / 18 |
| 2026-09-12 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-13 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-14 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-15 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-16 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-17 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-18 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-19 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-20 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-21 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-22 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-23 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-24 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-25 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-26 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-27 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-28 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-29 | $16.50 | $7,127,880,872 | 14 / 18 |
| 2026-09-30 | $16.50 | $7,127,892,910 | 14 / 18 |
| 2026-10-01 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-02 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-03 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-04 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-05 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-06 | $16.49 | $7,129,615,315 | 14 / 17 |
| 2026-10-07 | $16.49 | $7,129,842,587 | 14 / 17 |
| 2026-10-08 | $16.49 | $7,129,842,587 | 14 / 17 |
| 2026-10-09 | $16.49 | $7,128,609,436 | 14 / 17 |
| 2026-10-10 | $16.49 | $7,128,618,527 | 14 / 17 |
| 2026-10-11 | $16.49 | $7,128,618,527 | 14 / 17 |
| 2026-10-12 | $16.49 | $7,128,618,527 | 14 / 17 |
| 2026-10-13 | $16.49 | $7,128,618,527 | 14 / 17 |
| 2026-10-14 | $16.48 | $7,128,611,000 | 14 / 17 |
| 2026-10-15 | $16.48 | $7,128,633,496 | 14 / 17 |
| 2026-10-16 | $16.48 | $7,128,650,998 | 14 / 17 |
| 2026-10-17 | $16.48 | $7,128,650,998 | 14 / 17 |
| 2026-10-18 | $16.48 | $7,123,701,059 | 14 / 17 |
| 2026-10-19 | $16.48 | $7,123,701,059 | 14 / 17 |
| 2026-10-20 | $16.48 | $7,123,701,059 | 14 / 17 |
| 2026-10-21 | $16.48 | $7,123,701,059 | 14 / 17 |
| 2026-10-22 | $16.48 | $7,123,701,059 | 14 / 17 |
| 2026-10-23 | $16.50 | $7,122,908,550 | 13 / 17 |
| 2026-10-24 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-25 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-26 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-27 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-28 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-29 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-30 | $16.50 | $7,122,908,550 | 13 / 16 |
| 2026-10-31 | $16.51 | $7,122,908,550 | 13 / 16 |
| 2026-11-01 | $16.51 | $7,122,908,550 | 13 / 16 |
| 2026-11-02 | $16.51 | $7,122,908,550 | 13 / 16 |
| 2026-11-03 | $16.51 | $7,122,908,550 | 13 / 16 |
| 2026-11-04 | $16.52 | $7,151,568,677 | 13 / 16 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 18 Buy / Strong Buy · 4 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 7 recorded
2 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.